Ziling Liu

1.3k total citations · 1 hit paper
51 papers, 659 citations indexed

About

Ziling Liu is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Ziling Liu has authored 51 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Molecular Biology and 11 papers in Surgery. Recurrent topics in Ziling Liu's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Research Studies (10 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Ziling Liu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Research Studies (10 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Ziling Liu collaborates with scholars based in China, United States and Japan. Ziling Liu's co-authors include Rui Guo, Hong Wang, Xing Yang, Jing Gao, Shuai Qian, Jianjun Zhang, Yuan Gao, Hua He, Ji‐Fan Hu and Xi Chen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Applied Catalysis B: Environmental.

In The Last Decade

Ziling Liu

45 papers receiving 654 citations

Hit Papers

Immunotherapy: a promising approach for glioma treatment 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immunotherapy: a promising approach for glioma treatment
    2023 118 citations Xing Yang, Rui Guo et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ziling Liu China 15 201 200 96 91 89 51 659
Fangyuan Chen China 18 149 0.7× 444 2.2× 200 2.1× 117 1.3× 162 1.8× 72 1.2k
Jin‐Cong Zhuo Switzerland 14 208 1.0× 244 1.2× 58 0.6× 95 1.0× 71 0.8× 38 762
Diego A. Gianolio United States 14 268 1.3× 487 2.4× 78 0.8× 49 0.5× 46 0.5× 32 889
Weining Ma United States 13 301 1.5× 524 2.6× 73 0.8× 77 0.8× 44 0.5× 25 887
Eloisi Caldas-Lopes United States 7 152 0.8× 482 2.4× 50 0.5× 64 0.7× 38 0.4× 11 737
Joerg Berghausen Switzerland 6 162 0.8× 455 2.3× 51 0.5× 51 0.6× 56 0.6× 10 659
Narges K. Tafreshi United States 14 207 1.0× 366 1.8× 194 2.0× 98 1.1× 30 0.3× 26 842
Rianne Biemans Netherlands 17 142 0.7× 285 1.4× 226 2.4× 112 1.2× 13 0.1× 38 673
Neelu Kaila United States 23 121 0.6× 586 2.9× 85 0.9× 42 0.5× 37 0.4× 49 1.3k
Jim Sang United States 16 289 1.4× 1.0k 5.0× 95 1.0× 274 3.0× 61 0.7× 21 1.2k

Countries citing papers authored by Ziling Liu

Since Specialization
Citations

This map shows the geographic impact of Ziling Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziling Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziling Liu more than expected).

Fields of papers citing papers by Ziling Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ziling Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziling Liu. The network helps show where Ziling Liu may publish in the future.

Co-authorship network of co-authors of Ziling Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Ziling Liu. A scholar is included among the top collaborators of Ziling Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ziling Liu. Ziling Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Jiayu, Fei Teng, Haifeng Qin, et al.. (2025). Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer. Translational Lung Cancer Research. 14(4). 1408–1417. 1 indexed citations
3.
4.
5.
Zhang, Huimin, et al.. (2024). Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report. Frontiers in Oncology. 14. 1325999–1325999. 2 indexed citations
6.
Tang, Shi, Dan Zheng, Chen Chen, et al.. (2023). Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study. Frontiers in Oncology. 13. 1129989–1129989. 4 indexed citations
7.
Yang, Xing, et al.. (2023). Immunotherapy: a promising approach for glioma treatment. Frontiers in Immunology. 14. 1255611–1255611. 118 indexed citations breakdown →
8.
Shao, Xinxin, et al.. (2022). Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy. Journal of Materials Chemistry B. 10(8). 1291–1300. 13 indexed citations
9.
Jia, Lin, Naifei Chen, Xiaohong Chen, et al.. (2022). Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy. Frontiers in Immunology. 13. 1074906–1074906. 14 indexed citations
10.
Wang, Nanya, et al.. (2022). Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer. Frontiers in Oncology. 12. 1048999–1048999.
11.
Liu, Ziling, Xiao Yang, Zongfan Yang, et al.. (2022). Quinacridone based 2D covalent organic frameworks as efficient photocatalysts for aerobic oxidative Povarov reaction. Applied Catalysis B: Environmental. 312. 121406–121406. 29 indexed citations
12.
Jiang, Yan, Stéphane Avner, Aurélien A. Sérandour, et al.. (2021). ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis. Leukemia. 36(2). 549–554. 9 indexed citations
13.
Hu, Xiaolin, Mengmeng Dong, Xiao Liang, Ziling Liu, & Quanshun Li. (2021). Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin. International Journal of Nanomedicine. Volume 16. 471–480. 18 indexed citations
14.
15.
Zhao, Yan, Ziling Liu, Lin Wang, et al.. (2019). Genetic Variations Associated with Drug Resistance Markers in Asymptomatic Plasmodium falciparum Infections in Myanmar. Genes. 10(9). 692–692. 20 indexed citations
16.
Li, Yanan, et al.. (2019). Novel treatment of refractory / recurrent pulmonary hepatoblastoma. Pediatrics International. 62(3). 324–329. 11 indexed citations
17.
18.
Chen, Xi, Xu Wang, Hua He, et al.. (2015). Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer. PLoS ONE. 10(5). e0126276–e0126276. 42 indexed citations
19.
Ding, Xiao, He Cao, Xiao Chen, et al.. (2015). Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. Journal of Translational Medicine. 13(1). 158–158. 23 indexed citations
20.
Gao, Yuan, et al.. (2012). Coformer selection based on degradation pathway of drugs: A case study of adefovir dipivoxil–saccharin and adefovir dipivoxil–nicotinamide cocrystals. International Journal of Pharmaceutics. 438(1-2). 327–335. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fangyuan Chen Breakdown of academic impact, for papers by Jin‐Cong Zhuo Breakdown of academic impact, for papers by Diego A. Gianolio Breakdown of academic impact, for papers by Weining Ma Breakdown of academic impact, for papers by Eloisi Caldas-Lopes Breakdown of academic impact, for papers by Joerg Berghausen Breakdown of academic impact, for papers by Narges K. Tafreshi Breakdown of academic impact, for papers by Rianne Biemans Breakdown of academic impact, for papers by Neelu Kaila Breakdown of academic impact, for papers by Jim Sang
Rankless by CCL
2026